Introduction：Basic information about Olprinone CAS 106730-54-5, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Olprinone Basic information
| Product Name: | Olprinone |
| Synonyms: | 1,2-dihydro-5-imidazo(1,2-alpha)pyridin-6-yl-6-methyl-2-oxonicotinonitrile;5-(1,7-diazabicyclo[4.3.0]nona-2,4,6,8-tetraen-3-yl)-6-methyl-2-oxo-1h-pyridine-3-carbonitrile;OLPRINONE;5-(Imidazo[1,2-a]pyridine-6-yl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile;Olprinone [inn];3-phenylmethoxy-1-cyclobutanecarboxylic acid ethyl ester;1,2-Dihydro-5-(imidazo[1,2-a]pyridin-6-yl)-6-methyl-2-oxo-3-pyridinecarbonitrile;3-Pyridinecarbonitrile,1,2-dihydro-5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo- |
| CAS: | 106730-54-5 |
| MF: | C14H10N4O |
| MW: | 250.26 |
| EINECS: | |
| Product Categories: | API |
| Mol File: | 106730-54-5.mol |
|
Olprinone Chemical Properties
| Melting point | >300° |
| density | 1.34±0.1 g/cm3(Predicted) |
| storage temp. | Sealed in dry,Store in freezer, under -20°C |
| solubility | DMSO |
| form | Powder |
| pka | 6.59±0.10(Predicted) |
| color | White to off-white |
| InChI | InChI=1S/C14H10N4O/c1-9-12(6-11(7-15)14(19)17-9)10-2-3-13-16-4-5-18(13)8-10/h2-6,8H,1H3,(H,17,19) |
| InChIKey | JPAWFIIYTJQOKW-UHFFFAOYSA-N |
| SMILES | C1(=O)NC(C)=C(C2=CN3C=CN=C3C=C2)C=C1C#N |
| CAS DataBase Reference | 106730-54-5(CAS DataBase Reference) |
Safety Information
Olprinone Usage And Synthesis
| Description | Oprinone is an injection developed by Japan Co., Ltd. for the treatment of acute heart failure. It is a specific PDEⅢ inhibitor that selectively blocks cAMP and has high selectivity for the inhibition of human cardiac PDEⅢ. |
| Uses | Olprinone is used in the treatment of acute myocardial insufficiency. |
| Definition | ChEBI: Olprinone is a member of bipyridines. |
| Side effects | 1. In the treatment of heart failure, the main adverse reactions of opprinone are manifested in the circulatory system, including premature ventricular contraction, tachycardia, increased ventricular tachyarrhythmia, and increased heart rate. Electric monitoring;
2. As a vasodilator, patients with renal insufficiency should use it in low doses. Long-term oral administration may lead to increased long-term mortality due to large adverse reactions, so it is only used for a short period of time. |
| Synthesis | 4-(Dimethylamino)-3-(pyrimido[1,2-α]pyridin-6-yl)-3-buten-2-one and cyanoacetamide in dimethylformamide at 80~ Heating at 90°C for 12h to obtain Operinone.
|
| References | [1] Patent: CN106349246, 2017, A. Location in patent: Paragraph 0023; 0028; 0029 |
Olprinone Preparation Products And Raw materials
| Raw materials | N,N-Dimethylformamide-->2-Cyanoacetamide-->Imidazo[1,2-a]pyridine-6-boronic acid-->5-Bromo-3-cyano-2-hydroxy-6-methylpyridine-->Bis(triphenylphosphine)palladium(II) chloride-->Toluene-->Potassium carbonate |
